(CYRX) and the Role of Price-Sensitive Allocations
Cryoport Inc. (NASDAQ: CYRX) is showing divergent sentiment across all horizons, suggesting choppy conditions with no clear price positioning signal and elevated downside risk. Stock Traders Daily's AI models have generated three distinct trading strategies: a Position Trading Strategy (LONG), a Momentum Breakout Strategy (BREAKOUT), and a Risk Hedging Strategy (SHORT), each with specific entry, target, and stop loss points. Multi-timeframe analysis indicates neutral near-term, weak mid-term, and strong long-term signals, with their AI-generated signals providing detailed support and resistance levels.
Readystate Asset Management LP Sells 180,605 Shares of CryoPort, Inc. $CYRX
Readystate Asset Management LP reduced its stake in CryoPort, Inc. (NASDAQ:CYRX) by 37.2%, selling 180,605 shares and retaining 304,529 shares. This sale, valued at $2.887 million, was disclosed in a recent SEC filing. Additionally, CryoPort director Ramkumar Mandalam sold 11,570 shares, decreasing his ownership by 12.53%.
Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Cryoport, Inc. (Nasdaq: CYRX) announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 3, 2026, after U.S. markets close. The company will also release a detailed review document and host a questions-and-answers conference call the same day at 5:00 p.m. ET.
Cryoport’s new lab freezer runs without continuous liquid nitrogen
Cryoport (NASDAQ: CYRX) has launched the MVE Fusion® 800 Series, a new self-sustaining cryogenic freezer that eliminates the need for a continuous liquid nitrogen supply. This lab-sized unit maintains temperatures at or below -150°C, fits through standard doorways, and is aimed at facilities like research labs, hospital pharmacies, and biorepositories. The company believes this award-winning technology offers significant flexibility and cost benefits for biological material storage.
Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series
Cryoport's MVE Biological Solutions has launched the new Fusion® 800 Series, a self-sustaining cryogenic freezer that offers high-capacity storage, flexibility, and cost benefits in limited space environments. This innovative product eliminates the need for a continuous liquid nitrogen supply, providing exceptional reliability and safety in a compact design. The Fusion 800 is ideal for various medical and biological facilities, maintaining steady state temperatures at or below -150°C and addressing a longstanding challenge in cryogenic storage.
Responsive Playbooks and the CYRX Inflection
This article analyzes Cryoport Inc. (NASDAQ: CYRX), indicating weak near and mid-term sentiment but a strong long-term outlook. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis for support and resistance levels. The report highlights elevated downside risk despite potential long-term positivity due to a lack of immediate clear price positioning signals.
CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have issued a "Moderate Buy" consensus recommendation for CryoPort, Inc. (NASDAQ:CYRX), with an average 12-month price target of $12.83 based on reports from ten research firms. Notable recent price target increases include Needham & Company LLC to $12.00 and UBS Group to $12.50. Despite an insider selling 11,570 shares, the company exceeded Q4 earnings expectations with EPS of -$0.18 and revenue of $44.23 million, trading with a market cap of $476 million.
Understanding the Setup: (CYRX) and Scalable Risk
This article analyzes Cryoport Inc. (CYRX), identifying a weak near-term sentiment that could challenge long-term strength. It highlights a significant 39.3:1 risk-reward setup, targeting a 12.7% gain against a 0.3% risk, and presents three distinct AI-generated trading strategies for different risk profiles. The analysis points to divergent sentiment across various time horizons, suggesting potentially volatile market conditions for the stock.
CryoPort Inc (CYRX) Shares Down 2.89% on Jan 23
Shares of CryoPort Inc (CYRX) fell 2.89% on January 23, reaching an intraday low of $10.53 before closing at $10.60. Despite the dip, the average one-year price target from analysts suggests a 24.80% upside, indicating an "Outperform" status. However, GuruFocus' estimated GF Value for CYRX suggests a potential downside of 12.98% from the current price.
CryoPort, Inc. $CYRX Shares Purchased by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in CryoPort, Inc. by 663.2% in the third quarter of 2025, acquiring an additional 110,602 shares. This boosted their total holding to 127,280 shares, valued at approximately $1.21 million. Despite insider sales by Director Ramkumar Mandalam, CryoPort maintains a "Moderate Buy" consensus rating from analysts with an average target price of $12.83.
The Technical Signals Behind (CYRX) That Institutions Follow
This article from Stock Traders Daily analyzes Cryoport Inc. (NASDAQ: CYRX), highlighting a strong sentiment across all horizons supporting an overweight bias. It identifies a mid-channel oscillation pattern and an exceptional risk-reward short setup. The analysis provides specific institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Cryoport (NASDAQ:CYRX) shareholders are up 10% this past week, but still in the red over the last five years
Cryoport (NASDAQ:CYRX) shareholders have seen a 10% gain this past week, but the stock is still down 84% over the last five years, indicating significant long-term losses. While the company's revenue has increased by 11% per year over the last half-decade, its continued unprofitability and a 13% annual stock price decline suggest investor concern about its future sustainability. Despite recent short-term gains, the long-term performance remains a significant area of concern for investors.
Cryoport (NASDAQ:CYRX) shareholders are up 10% this past week, but still in the red over the last five years
Cryoport (NASDAQ:CYRX) shareholders have experienced a 10% increase this past week, but the stock is still down 84% over the last five years. Despite a 11% annual revenue growth over the past five years, the share price has fallen by 13% annually, indicating investor concern over continuous losses. The company recently added US$50m to its market cap, and while the long-term performance is concerning, recent short-term gains might hint at a brighter future.
Cryoport (NASDAQ:CYRX) shareholders are up 10% this past week, but still in the red over the last five years
Cryoport (NASDAQ:CYRX) shareholders have seen a 10% increase in their investment over the past week, yet the stock remains significantly down by 84% over the last five years. Despite this long-term decline, the company has reportedly added US$50 million to its market cap recently. The article examines Cryoport's revenue growth of 11% per year over five years, noting that this still led to a 13% annual stock price fall, suggesting investor concerns about continued losses despite growth.
CryoPort, Inc. (NASDAQ:CYRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
CryoPort, Inc. (NASDAQ:CYRX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $12.83. This comes as various brokers like UBS, Needham, and BTIG have recently raised their price targets for the stock. Despite a director's sale of 11,570 shares, insiders still own over 10% of the company, which boasts strong institutional ownership at nearly 93% and exceeded revenue and EPS estimates in its latest quarter.
CryoPort (NASDAQ:CYRX) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?
CryoPort (NASDAQ:CYRX) shares recently climbed above their 200-day moving average, reaching $9.55 on trading volume of 291,829, which could be a bullish technical indicator. The company beat revenue and EPS estimates in its latest quarter, and analysts generally have a "Moderate Buy" rating with a consensus price target of $12.83. Despite positive analyst sentiment and institutional ownership of nearly 93%, an insider recently sold a significant number of shares, and the company still forecasts negative full-year EPS.
How Cryoport Inc. (CYRX) Affects Rotational Strategy Timing
This article analyzes Cryoport Inc. (CYRX) and its impact on rotational strategy timing, highlighting a strong near-term sentiment with a long-term positive bias. It presents different institutional trading strategies for various risk profiles, including position trading, momentum, and risk hedging, along with multi-timeframe signal analysis. The report also emphasizes real-time signals, risk-reward ratios, and personalized alerts available through their platform.
CryoPort, Inc. $CYRX Shares Bought by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly increased its stake in CryoPort, Inc. (NASDAQ:CYRX) by 37.4%, acquiring an additional 408,263 shares. This raises their total holdings to 1,498,774 shares, valued at $14.21 million. While institutional investors now own 92.9% of the company, a director recently sold 11,570 shares, reducing his ownership by 12.53%.
Discipline and Rules-Based Execution in CYRX Response
This article discusses the discipline and rules-based execution in response to Cryoport Inc. (NASDAQ: CYRX), highlighting weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies resistance being tested and presents an exceptional risk-reward short setup. The piece also details institutional trading strategies generated by AI models, including position trading, momentum breakout, and risk hedging strategies for CYRX.
Don't Ignore The Insider Selling In Cryoport
An independent director at Cryoport, Ramkumar Mandalam, recently sold US$116k worth of stock, representing 17% of his holding. This follows an earlier larger sale by Chairman Jerrell Shelton for US$1.0m worth of shares. While insiders still collectively own US$16m worth of shares (3.3% of the company), the consistent selling activity without any recent purchases suggests caution is warranted, despite no explicit recommendation to buy or sell.
Don't Ignore The Insider Selling In Cryoport
An independent director at Cryoport, Inc. recently sold US$116k worth of shares, representing 17% of their holding. This follows a larger sale by the Chairman last year for US$1.0m, indicating a trend of insider selling. Despite insiders owning 3.3% of the company, the consistent selling without corresponding purchases raises caution for potential investors.
Don't Ignore The Insider Selling In Cryoport
An independent director at Cryoport, Inc. recently sold a significant portion of their stock, raising concerns about insider sentiment. While insiders own approximately 3.3% of the company, there have been no insider purchases reported in the last year, only sales. This selling activity suggests a cautious stance from insiders, prompting further investigation into the company's financial health.
Ramkumar Mandalam Sells 11,570 Shares of CryoPort (NASDAQ:CYRX) Stock
CryoPort Director Ramkumar Mandalam sold 11,570 shares of the company's stock for $115,584.30, reducing his stake by 12.53%. The transaction, which occurred on December 10th, leaves him with 80,758 shares valued at approximately $806,772. This insider selling comes amidst CryoPort's recent financial performance, which exceeded quarterly expectations with an EPS of $(0.18) and revenue of $44.23 million.
Insider Sell Alert: Ramkumar Mandalam Sells 11,570 Shares of CryoPort Inc (CYRX)
Ramkumar Mandalam, a Director at CryoPort Systems and CryoPort Inc (CYRX), sold 11,570 shares of the company on December 10, 2025. This transaction reduces his total holdings to 80,758 shares, following a pattern of insider sells with no buys over the past year. CryoPort Inc, a provider of temperature-controlled supply chain solutions, is currently trading at $9.99 per share and is considered fairly valued based on its GF Value.
CryoPort, Inc. (NASDAQ:CYRX) Given Average Rating of "Moderate Buy" by Brokerages
CryoPort, Inc. (NASDAQ:CYRX) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $12.83. Several analysts recently adjusted their price objectives, reflecting a generally positive outlook on the company. The company reported better-than-expected quarterly earnings and had significant insider selling activity balanced by hedge fund investment.
Insider Sell Alert: Ramkumar Mandalam Sells 11,570 Shares of CryoPort Inc (CYRX)
Ramkumar Mandalam, a Director at CryoPort Systems (a subsidiary of CryoPort Inc (CYRX)), sold 11,570 shares of the company on December 10, 2025. This transaction reduces his total ownership to 80,758 shares. CryoPort Inc, a provider of temperature-controlled supply chain solutions for the life sciences industry, is currently trading at $9.99 per share, with a GuruFocus Value of $9.10, indicating it is fairly valued.
Norges Bank Invests $1.62 Million in CryoPort, Inc. $CYRX
Norges Bank recently acquired a significant stake in CryoPort, Inc. (NASDAQ:CYRX), investing approximately $1.62 million for 217,700 shares, representing about 0.43% ownership. This move aligns with increased institutional interest as CryoPort showed a positive earnings and revenue beat and holds a consensus "Moderate Buy" rating from analysts. CryoPort's stock currently trades around $10 with a market capitalization of $503.70 million.
Thematics Asset Management Purchases 216,937 Shares of CryoPort, Inc. $CYRX
Thematics Asset Management significantly increased its stake in CryoPort, Inc. by 12.8%, acquiring an additional 216,937 shares, bringing their total ownership to 1,914,885 shares valued at $14.285 million. CryoPort, trading at $9.54, has a "Moderate Buy" consensus rating from analysts with an average target price of $12.83, following raised price targets from several firms. The company recently surpassed quarterly revenue and EPS estimates, reporting $44.23 million in revenue and ($0.18) EPS against a consensus of ($0.23).
Kennedy Capital Management LLC Acquires Shares of 547,402 CryoPort, Inc. $CYRX
Kennedy Capital Management LLC has acquired a new stake of 547,402 shares in CryoPort, Inc. (NASDAQ:CYRX), valued at approximately $4.08 million, representing 1.09% of the company. Institutional investors collectively own 92.90% of CryoPort's stock, with other firms like Acadian Asset Management and Norges Bank also adjusting their holdings. Analysts maintain a "Moderate Buy" rating for CryoPort with an average target price of $12.83, despite recent insider share sales.
Philadelphia Trust Co. Boosts Holdings in CryoPort, Inc. $CYRX
Philadelphia Trust Co. significantly increased its stake in CryoPort, Inc. (NASDAQ:CYRX) by 160.6% in the second quarter, owning 0.50% of the company's stock valued at $1.88 million. This comes as CryoPort beat earnings expectations with an EPS of ($0.18) and revenue of $44.23 million, contributing to a "Moderate Buy" consensus rating from analysts with an average price target of $12.83. However, a director recently sold a substantial portion of their holdings.
Cryoport Inc expected to post a loss of 21 cents a share - Earnings Preview
Cryoport Inc (CYRX) is expected to report a loss of 21 cents per share on November 4 for the quarter ending September 30, 2025, with an anticipated 27.0% decrease in revenue. Analysts currently rate the shares as "buy," with a median 12-month price target of $13.00. The company's past quarterly performance has shown a mix of beats and misses on earnings estimates.
Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain
Cryoport, Inc. announced that its subsidiary, Cryoport Systems, has achieved ISO 21973:2020 certification for the transportation of human cells for therapeutic use. This makes Cryoport the first global supply chain solutions company to earn this certification, reinforcing its leadership in ensuring the highest safety, traceability, and integrity standards for cell and gene therapies. The certification highlights Cryoport's commitment to critical conditions monitoring and risk minimization in regenerative medicine supply chains, extending these standards across its life sciences operations.
A Look at Cryoport's Valuation as New Monitoring Technology Enhances Life Sciences Logistics - Yahoo Finance
Cryoport (CYRX) has introduced new monitoring technology for its life sciences logistics solutions, leading to a recent surge in its stock price. Despite recent gains, the company's long-term shareholder returns remain negative. The article assesses Cryoport's valuation, suggesting it is undervalued based on the accelerating adoption of cell and gene therapies and the potential for significant earnings turnaround.
Can Cryoport's (CYRX) Smart Monitoring Upgrade Hint at a Shift in Cold Chain Leadership? - Yahoo Finance
Cryoport (CYRX) has upgraded its MVE Biological Solutions with new integrated smart monitoring for its cryogenic dewars, enhancing data management for critical temperature-sensitive materials. This innovation addresses growing demands for safety and compliance in life sciences logistics but does not immediately reduce Cryoport's revenue concentration risk on a few commercial therapy clients. Despite these technological advancements, the company's financial performance remains heavily dependent on the sustained commercialization success of cell and gene therapies.
CryoPort (NASDAQ:CYRX) Reaches New 52-Week High - Time to Buy? - MarketBeat
CryoPort, Inc. (NASDAQ:CYRX) recently achieved a new 52-week high of $11.34 amidst robust trading, following positive analyst ratings that raised target prices to $15.00 and $16.00. Despite a director's sale of shares reducing their ownership by 32.78%, institutional investment in CYRX has seen significant increases, with 92.90% of the stock now owned by institutional investors. The company's financial performance includes a market cap of $536.25 million and a P/E ratio of 8.05, though it missed Q2 EPS estimates while exceeding revenue expectations.
CryoPort (NASDAQ:CYRX) Trading Up 9.1% - Should You Buy? - MarketBeat
CryoPort (NASDAQ:CYRX) saw its stock price increase by 9.1% to $10.17, despite a significant drop in trading volume. Analysts have issued "Moderate Buy" ratings with price targets between $13.00 and $16.00. The company reported revenue of $45.45 million, exceeding expectations, but missed EPS estimates with a net loss of ($0.29).
Wealth Enhancement Advisory Services LLC Purchases Shares of 16,121 CryoPort, Inc. $CYRX
Wealth Enhancement Advisory Services LLC has acquired a new position of 16,121 shares in CryoPort, Inc. (CYRX). This comes as several institutional investors have adjusted their holdings in CryoPort, with significant increases from firms like Readystate Asset Management LP and Acadian Asset Management LLC. Analyst ratings for CryoPort are generally positive, with a consensus of “Moderate Buy” and an average target price of $12.56.
MVE Biological Solutions, A Cryoport Company, Introduces Real-Time Integrated Condition Monitoring Systems For Cryogenic Dewars
MVE Biological Solutions, a Cryoport Company, has launched new real-time integrated condition monitoring systems for its cryogenic dewars. These systems, powered by Tec4Med, integrate SmartTag™ or CryoBeacon™ directly into dewar lids, providing centralized condition monitoring and data management through the MVECloud™ platform. This initiative aims to provide enhanced visibility, real-time alerts, and reporting for critical biological material storage and transport.
Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, France
Cryoport, Inc. announced the launch of its new 55,000-square-foot Global Supply Chain Center in Louvres, France, strategically located near the Paris Charles de Gaulle Airport. This facility expands Cryoport Systems' global network, offering comprehensive temperature-controlled supply chain solutions for the life sciences, including biologistics, BioServices, and future cryopreservation services. The center will immediately support biopharma logistics and will gradually add advanced services for clinical and commercial cell and gene therapy programs.
Cryoport Adds New Global Supply Chain Center in Louvres, France
Cryoport Inc., through its subsidiary Cryoport Systems, has launched a new Global Supply Chain Center in Louvres, France, near the Paris Charles de Gaulle Airport. This strategic expansion strengthens Cryoport Systems’ network by providing end-to-end temperature-controlled supply chain solutions for advanced therapies, including cell and gene therapies, biologics, and animal health products. The facility will offer 24-hour worldwide dispatch capabilities and will progressively add BioServices, biostorage, and QP drug management, supporting both clinical and commercial programs.
Earnings call transcript: Cryoport Q2 2025 sees revenue growth, stock dips
Cryoport Inc. announced strong Q2 2025 financial results, with EPS of $2.05 (beating forecasts by 859.26%) and revenue of $45.5 million (exceeding expectations by 9.01%). Despite this performance, the stock declined by 6.01% in aftermarket trading. The company reaffirmed its full-year 2025 revenue guidance, emphasizing growth in commercial cell and gene therapy and strategic partnerships like the one with DHL.
Investors in Cryoport (NASDAQ:CYRX) have unfortunately lost 79% over the last three years
Cryoport (NASDAQ:CYRX) investors have experienced a significant 79% loss over the past three years, despite a recent 35% gain in the last quarter. The company is not currently profitable, and its revenue has declined by 2.1% annually over the last three years, which typically deters investors. This performance highlights the challenges faced by money-losing companies that fail to achieve substantial revenue growth.
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet
Cryoport (NASDAQ:CYRX) currently shows a low price-to-sales (P/S) ratio of 1.4x, which could indicate bullish signals compared to the broader Life Sciences industry. However, this low P/S ratio is likely attributed to inconsistent past revenue growth and a forecast of diminishing returns with a 4.3% annual revenue decrease over the next three years, contrasting with the industry's 7.2% expansion. The article concludes that improved revenues are necessary for Cryoport's stock to find its footing and for its P/S ratio to rise.
Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group
Cryoport, Inc. announced the completion of the divestiture of its specialty courier business, CRYOPDP, to DHL Group for approximately $200 million. Concurrently, Cryoport and DHL have formed a strategic partnership to enhance global life sciences and healthcare supply chain services. This move is expected to improve Cryoport's positioning in APAC and EMEA regions and intensify its focus on the rapidly growing Regenerative Medicine market.
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable
Cryoport, Inc.'s CEO, Jerry Shelton, received total compensation of US$1.9 million in 2024, which is below the industry average for similar-sized life sciences companies. Despite a 30% increase in EPS over three years, shareholders have seen a 78% loss in total return over the same period, suggesting a disconnect between company performance and shareholder value. The upcoming AGM on June 6th will allow shareholders to address these concerns and influence the company's future direction.
DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"
DHL Group has acquired 100% of CRYOPDP from Cryoport to enhance its specialized pharma logistics capabilities and expand in the life science and healthcare sector. This acquisition aligns with DHL's Strategy 2030 to lead in healthcare logistics, leveraging CRYOPDP's expertise in clinical trials and cell & gene therapies. Concurrently, DHL and Cryoport have formed a strategic partnership to strengthen their respective supply chain service offerings globally.
Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
Cryoport (NASDAQ:CYRX) has debt but also maintains a net cash position of US$62.3m, indicating that its liquid assets align with its short-term liabilities. Despite having no earnings and burning US$38m in cash over the last year, the company's net cash position could sustain growth for at least two years. The article suggests that while debt makes investment risky for companies not generating free cash flow, Cryoport's balance sheet appears sufficiently liquid.
Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies
Cryoport, Inc. has introduced its new Cryoport Express® Cryogenic HV3 Shipping System, designed to enhance the transport of biologics and temperature-sensitive therapies. This innovative system aims to improve patient accessibility in underserved areas by enabling transport on narrow-bodied aircraft and offering superior protection and temperature control. It also features improved mobility, scalability, and ease of use for clinical and manufacturing sites.
Cryoport reports Q4 EPS ($1.31) with items, consensus (29c)
Cryoport reported Q4 EPS of ($1.31) with items, significantly below the consensus of (29c), and Q4 revenue of $57.26M, slightly missing the consensus of $58.4M. The EPS includes a substantial non-cash impairment charge of $49.6M related to goodwill. Despite challenging operating conditions, the company highlighted growth in its services business and BioStorage/BioServices revenues, as well as an increase in supported clinical trials.
Cell therapy weekly: commercial agreement to manufacture CASGEVY
Lonza has entered into a long-term commercial agreement with Vertex Pharmaceuticals to manufacture CASGEVY®, the first CRISPR/Cas9 gene-edited therapy for sickle cell disease and beta thalassemia. CASGEVY® will be produced at Lonza’s cGMP facilities in Geleen, Netherlands, with plans to expand to Portsmouth, NH, in 2025. Additionally, SK pharmteco and Cryoport have partnered to offer integrated logistics and manufacturing services, and Terumo BCT and Nova Biomedical are collaborating to automate cell culture analyses.
